News Releases

June 16, 2021
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 16, 2021-- Verve Therapeutics , a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of its initial public offering of 14,035,789 shares of its common stock
Displaying 1 - 10 of 12